

PTO  
SEP 25 2003  
PATENT & TRADEMARK

09-26-03

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐


Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  <i>(to be used for all correspondence after initial filing)</i>	<b>Application Number</b>	10/618,288	
	<b>Filing Date</b>	April 25, 2003	
	<b>First Named Inventor</b>	Thomas E. Barta, et al.	
	<b>Group Art Unit</b>	Unknown	
	<b>Examiner Name</b>	Unknown	
<b>Total Number of Pages in This Submission</b>		<b>Attorney Docket Number</b>	00988/1/US (6794-000053/US)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Response  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Second Supplemental Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application)  <input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  <b>FORM HDP-1449</b> <b>29 References</b> <b>Return Receipt Postcard</b>
<b>Remarks</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	David M. Gryte, PTO Reg. No. 41,809 Harness, Dickey & Pierce, P.L.C.
Signature	
Date	September 25, 2003

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450			
on this date: September 25, 2003			
Typed or printed name	David M. Gryte		
Signature		Date	September 25, 2003

EV 311408173 US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Thomas E. Barta, et al.  
Serial No: 10/618,288  
Filed: April 25, 2003  
For: Piperidiny- and Piperazinyl- Sulfonylmethyl Hydroxamic Acids and  
Their Use as Protease Inhibitors  
Confirmation No: TBA  
Art Unit: TBA  
Examiner: TBA  
Attorney Ref: 00988/1/US  
HDP Ref: 6794-000053/US

September 25, 2003

**SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 CFR §1.97 and §1.98, Applicants submit the enclosed supplemental Form PTO-1449 and copies of all documents listed on that form.

In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration and that the Examiner cite each document of record in the prosecution history of the present application by initialing Form PTO-1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a listed document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this Information Disclosure Statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.5, but by listing such documents Applicants are not admitting that such documents are necessarily relevant or prior art. Applicants intend no representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104(a) and §1.106(b) and, in the course of such

EV 311408173 US

search, will review for relevance every document listed on the attached form even if not initialed.


Applicants make no representation as to the accuracy of any translation provided with this Information Disclosure Statement.

Applicants request early and favorable consideration.

\* \* \* \* \*

Applicants believe that they do not owe any fee in connection with this Information Disclosure Statement. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.


Respectfully submitted,



David M. Gryte, PTO Reg. No. 41,809  
Harness, Dickey & Pierce  
7700 Bonhomme, Suite 400  
St. Louis, Missouri 63105  
(314) 726-7500 (tel)  
(314) 726-7501 (fax)

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service on **September 25, 2003** with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to **Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.



DMG/PML

FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Sheet 1 of 2

ATTORNEY DOCKET NO.

SERIAL NO.

00988/1/US (6794-000053/US)

10/618,288

APPLICANT

Thomas E. Barta, et al.

FILING DATE

GROUP

April 25, 2003

Unknown

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate)

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes	No
56.		WO 00/46221	8/10/00	PCT	C07D 405/12		
57.		WO 00/50396	8/31/00	PCT	C07D 211/66		
58.		WO 00/59874	10/12/20	PCT	C07C 259/06		
59.		WO 00/69819	11/23/20	PCT	C07D 211/16		
60.		WO 00/69821	11/23/00	PCT	C07D 211/66		
61.		WO 00/74681	12/14/00	PCT	A61K 31/451		
62.		WO 02/092588	11/21/02	PCT	C07D 309/08		
63.		WO 03/007930	1/30/03	PCT	A61K 31/166		

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)

Ref. Desig	Examiner's Initials	
64.		Brown, "Synthetic Inhibitors of Matrix Metalloproteinases"; <i>Matrix Metalloproteinases</i> , pp. 243-261 (Academic Press, San Diego, CA, Eds. Park, W.C., & Mecham, R.P., 1998)
65.		Dack, et al., "Preparation of N-hydroxytetrahydropyridylsulfonylacetamides and related compounds as matrix metalloprotease inhibitors," CA 131:44740 (1999) [CA Plus Accession No. 1999:388166]
66.		Denis, et al., "Matrix metalloproteinase inhibitors: Present achievements and future prospects," <i>Invest New Drugs</i> , 15:175-185 (1997).
67.		Freije, et al., "Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas," <i>J. Biol. Chem.</i> , 269(24), pp. 16766-16773 (1994)
68.		Gearing, et al., "Processing of tumour necrosis factor- $\alpha$ precursor by metalloproteinases," <i>Nature</i> , 370:555-557 (1994).

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 311408173 US



FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION  
(Use several sheets if necessary)

Sheet 2 of 2

ATTORNEY DOCKET NO.

00988/1/US (6794-000053/US)

SERIAL NO.

10/618,288

APPLICANT

Thomas E. Barta, et al.

FILING DATE

April 25, 2003

GROUP

Unknown

69.	Gu, et al., "S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death," <i>Science</i> , 297, 1186-1190 (2002)
70.	Hughes, et al., "Monoclonal antibodies that specifically recognize neopeptide sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism <i>in situ</i> and <i>in vitro</i> ," <i>Biochem. J.</i> , 305, 799-804 (1995)
71.	Kenyon, et al., "A model of angiogenesis in the mouse cornea," <i>Invest Ophthalmol. Vis. Sci.</i> , 37(8):1625-1632 (1996).
72.	Knight, et al., "A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases," <i>FEBS Lett.</i> , 296(3):263-266 (1992).
73.	Kuzmic, et al., "High-throughput screening of enzyme inhibitor: simultaneous determination of tight-binding inhibition constants and enzyme concentration," <i>Anal. Biochem.</i> , 286, 45-50 (2000)
74.	Luckow, et al., "Insect Cell Expression Technology", <i>Protein Engineering: Principles and Practice</i> , pp. 183-218 (John Wiley & Sons, Inc., New York, NY, Edited by J.L. Cleland et al., 1996)
75.	Luckow, et al., "Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in <i>Escherichia coli</i> ," <i>J. Virol.</i> , 67(8):4566-4579 (1993)
76.	McClure, et al., "Matrix metalloproteinase (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases," CA 131:125454 (1999) [CA Plus Accession No. 1999:468334]
77.	McGeehan, et al., "Regulation of tumour necrosis factor- $\alpha$ processing by a metalloproteinase inhibitor," <i>Nature</i> , 370:558-561 (1994).
78.	Mitchell, et al., "Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage," <i>J. Clin. Invest.</i> , 97(3):761-768 (1996).
79.	Rasmussen, et al., "Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat," <i>Pharmacol. Ther.</i> , 75(1):69-75 (1997).
80.	Reboul, et al., "The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes," <i>J. Clin. Invest.</i> , 97(9):2011-2019 (1996).
81.	Schwartz, et al., "Synthetic inhibitors of bacterial and mammalian interstitial collagenases," <i>Prog. In Med. Chem.</i> , 29:271-334 (1992).
82.	Tang, "ADAMTS: a novel family of extracellular matrix proteases," <i>Int'l J. Biochem. Cell Biol.</i> , 33, 33-44 (2001)
83.	Woessner, "The Matrix Metalloproteinase Family," <i>Matrix Metalloproteinases</i> , pp. 1-14 (Academic Press, San Diego, CA, Eds. Parks, W.C. & Mecham, R.P., 1998)
84.	A partial search report from PCT Appl. No. PCT/US03/13123

Examiner:

Date Considered:

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.